Assessing disease progression using a composite endpoint

Statistical Methods in Medical Research

Volumn 16, Issue 1, 2007, Pages 31-49

  Wong, Weng Kee ^a   Furst, Daniel E ^a   Clements, Philip J ^b   Streisand, Jim B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLAMINE;

ARTICLE; CHRONIC DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; LOW DRUG DOSE; LUNG FUNCTION TEST; OUTCOME ASSESSMENT; SAMPLE SIZE; SCLERODERMA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ANTIRHEUMATIC AGENTS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIERS ESTIMATE; OUTCOME ASSESSMENT (HEALTH CARE); PENICILLAMINE; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE; SCLERODERMA, DIFFUSE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 33847026355     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207070632     Document Type: Article

References (17)

1. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40: 1079-87.
2. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-98.
3. Lefkopoulou M, Ryan L. Global tests for multiple binary outcomes. Biometrics 1993; 49: 975-88.
4. Tilley BC, Pillemer SR, Heyse SP, Li S, Clegg DO, Alarcon GS, the Mira Trial Group. Global statistics tests for comparing multiple outcomes in rheumatoid arthritis trials. Arthritis and Rheumatism 1999; 42: 1879-88.
5. David T. Felson, Jennifer J. Anderson, Maarten Boers, Claire Bombardier, Daniel Furst, Charles Goldsmith, Linda M. Katz, Robert Lightfoot, Jr., Harold Paulus, Vibeke Strand, Peter Tugwell, Michael Weinblatt, James Williams H, Frederick Wolfe, Stephanie Kieszak, ACR Preliminary Definition of Improvement in Rheumatoid Arthritis, Arthritis and Rheumatism 1995; 38: 727-35.
6. Donner A, Eliasziw M. Statistical implications o the choice between a dichotomous or continuous trait in studies of interobserver agreement. Biometrics 1994; 50: 550-5.
7. Altaye M, Donner A Eliasziw M. A general goodness-of-fit approach for inference procedures concerning the kappa statistic. Statistics in Medicine 2001; 20: 2479-88.
8. Herrington EC. The desirability function. Industrial Quality Control 1965; 21: 494-8.
9. Shih M, Gennings C, Chinchilli VM, Carter WH Jr. Titrating and evaluating multli-drug regimens within subjects. Statistics in Medicine 2003; 22: 2257-79.
10. Hendriks MMWB, de Boer JH, Smilde AK, Doornbos DA. Multi-criteria decision making. Chemometrics and Intelligent Laboratory Systems 1992; 16: 175-91.
11. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally, E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis. Analysis of a two year double-blind, randomized controlled clinical trial. Arthritis and Rheumatism 1999; 42: 1194-203.
12. Derringer G, Suich R. Simultaneous optimization of several response variables. Journal of Quality Technology 1980; 12: 214-19.
13. Desiree MFM van der Heijde, van't Hof MA, van Riel PLCM, Theunisse LAM, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Juding disease activity in clinical practice in rheumatoid arthritis; first step in the development of a disease activity score. Annals of the Rhematic Diseases 1990; 49: 916-20.
14. Desiree MFM van der Heijde, van't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases 1992; 51: 177-81.
15. Donner A Altaye M. Selected issues in the design of studies of interobserver agreement. In Berger MPF, Wong WK, eds. Applied optimal designs. John Wiley, 2005.
16. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Linda M. Katz, Robert Lightfoot, Jr., Harold Paulus, Vibeke Strand, Peter Tugwell, Michael Weinblatt, James Williams H, Frederick Wolfe, Stephanie Kieszak, The American College of Rhematology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995; 38: 727-35.
17. Paulus HE, Oh MS, Sharp JT, Gold RH, Wong WK, Park GS, Bulpitt KJ. Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. Arthritis and Rheumatism 2004; 50: 1083-96.